Transline Technologies Unlisted Shares: Power Transmission Bet?

Transline Technologies has been developing one of the most convincing growth tales in India’s private equity market – although not in power transmission in the literal sense, but in the connection of India’s digital and physical security infrastructure. Now, having filed its DRHP and received its SEBI observation letter, it is ready to take off for its IPO. Here is what the figures say about the validity of the current entry price.

What Does Transline Actually Do?

Transline Technologies is an integrated solutions provider in video surveillance, biometrics, and IT infrastructure, offering services from hardware integration and installation to the provision of software solutions and warranty management. The company’s clientele is predominantly in sectors such as government, PSU, BFSI, health care, retail, and education, making its revenue streams less susceptible to consumer discretion and more secure and reliable.

• Founded: 2001, headquartered in Delhi

• Core segments: Security & surveillance systems, IT infrastructure integration, Electronics System Design & Manufacturing (ESDM)

• Client base: 100+ major corporations including Fortune 500 clients, alongside government and PSU contracts

• IPO status: DRHP filed with SEBI on 7 August 2025; SEBI's observation letter received 23 January 2026

The broader backdrop matters here too. India has been pushing hard on domestic electronics manufacturing through PLI-linked incentives, and demand for surveillance systems, biometric access control, and secure IT infrastructure has grown steadily across smart city projects, banking security upgrades, and public safety programmes. Transline's ESDM arm, which covers everything from design to integration for sectors like automotive, industrial, and telecom, gives it a foothold in this manufacturing shift rather than leaving the business purely reliant on trading margins from imported hardware.

The Growth Story: Revenue and Profitability

Transline's FY25 revenues grew 64% year on year, driven by conversion of a strong FY24 order backlog (Rs 255 Cr). The growth rate of FY26 witnessed moderation but still remained impressive in the context of the scale of the business.

A few things stand out here:

• Margin recovery, not just growth. EBITDA margin improved to 22.36% in FY26 after dipping from a FY24 peak of 23.14% to 21.39% in FY25 — the initial compression likely reflected mix dilution as the company absorbed a much larger, lower-margin project base during its 64% growth surge; FY26 shows better cost absorption as execution matured.

• Bottom-line growth outpacing revenue. PAT margin expanded faster than EBITDA margin, suggesting operating leverage is starting to show through at the net level, not just at the operating line.

• Government/PSU concentration. Roughly 66% of FY25 revenue came from government agencies, state departments, urban local bodies, and PSUs — a segment that offers revenue visibility and payment discipline, but also ties growth to public procurement cycles and budget timing.

  
  

Balance Sheet and Return Ratios: A Mixed Picture

Not every metric moved in the same direction, and that’s worth flagging rather than glossing over.

• Liquidity strengthened: Current ratio improved to 1.81x in FY26 from 1.73x in FY25, continuing a multi-year recovery from a 1.55x low in FY23 — a sign the company has built more working capital cushion even as revenue scaled more than 4x over the period.

• ROCE improved: Rising to 27.15% in FY26 from 25.77% in FY25, as EBIT grew faster (49% y-o-y) than capital employed — a genuinely encouraging capital-efficiency signal.

• ROE and ROA both softened: ROE fell to 32.87% from 36.86%, and ROA eased to 14.86% from 15.67%, as total assets and equity grew faster than net profit — largely a function of the balance sheet expanding (receivables, loans and advances) to support the higher revenue base rather than any operating weakness.

• Order book stood at Rs 198.6 Cr as of end-FY25 — smaller than the Rs 255 Cr FY24 figure, worth tracking as a forward growth indicator alongside quarterly execution updates.

  
  

Key Takeaways

• Revenue growth remains strong (31.7% in FY26) even as it moderates from FY25's exceptional 64% surge — a healthier, more sustainable trajectory.

• Margins are recovering, not deteriorating, with EBITDA and PAT margins both expanding in FY26 after FY25 dilution.

• Capital efficiency is improving (ROCE up), even as ROE/ROA softened on balance sheet growth — a distinction worth understanding rather than treating as a blanket red flag.

• DRHP is filed, and SEBI has responded - this is a live, advancing IPO candidate, not a speculative "maybe someday" story.

• ~66% government/PSU revenue concentration cuts both ways: strong revenue visibility, but exposure to public-sector budget and payment cycles.

• Price discovery is inconsistent across platforms - verify current quotes and lot sizes directly before transacting.

Transline is among the most fundamental stocks in this area, with an IPO timetable that is progressing nicely, improved margins, and an entrenched client base, dominated by the government. However, the extremely wide band on the unlisted price and declining ROE/ROA ratios merit further scrutiny before taking any position.

​